Drug Trial Radar · NCT07884136
RBD1119 in Coronary Artery Disease (CAD)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Sep 30, 2027
Study completion Mar 18, 2028
Sponsor
- Lead sponsor
- Ribocure Pharmaceuticals ABIndustry
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death. Despite contemporary secondary prevention including lipid lowering, revascularization when indicated, and antiplatelet therapy, participants with established CAD, particularly those post-ACS, remain at clinically meaningful residual risk of recurrent atherothrombotic events. Intensifying antithrombotic therapy can reduce ischemic events but typically increases bleeding, as exemplified by the addition of low dose rivaroxaban to aspirin in stable atherosclerotic disease. This persistent efficacy-safety trade-off supports development of antithrombotic approaches that reduce pathological thrombosis while preserving hemostasis. RBD1119 is a GalNAc-conjugated siRNA that targets factor XI mRNA in hepatocytes. The GalNAc moiety binds the asialoglycoprotein receptor on hepatocyte surfaces, enabling receptor mediated endocytosis and preferential hepatic uptake. Once internalized, RBD1119 mediates cleavage of factor XI mRNA via the RNA interference pathway, reducing hepatic factor XI expression and lowering circulating factor XI levels. This multicenter, randomized, double-blind, placebo-controlled, phase II trial will evaluate the PD, safety, and PK of subcutaneously administered RBD1119 in participants with stable coronary artery disease (CAD).
Conditions
- Stable Coronary Artery Disease
Interventions
RBD1119Drug
RBD1119, active drug
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectiveTime frame: Week 8
- Primary endpointTime frame: Week 8
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Gabinet Kardiologiczno-Internistyczny
Gdynia, Poland
Cardiology Department, SPS Szpital Zachodni im św Jana Pawła II
Grodzisk Mazowiecki, Poland
Centrum Medyczne Vitamedicum itw
Krakow, Poland
Specjalistyczna Praktyka Lekarska Ewa Mirek Bryniarska
Krakow, Poland
Department of Cardiology, The Copper Health Centre MCZ
Lubin, Poland
Velocity Nova Sp. z o.o. site: Velocity Lublin
Lublin, Poland
balsam MEDICA medical centre
Warsaw, Poland
Centrum Medyczne LUX MED (LUX MED Sp. z o.o.)
Warsaw, Poland
Klinika Sienna
Warsaw, Poland
Przychodnia Care Access Warszawa
Warsaw, Poland
Velocity Nova Sp. z o.o. site: Velocity Zamość
Zamość, Poland
Kardiologi VO Hjärt- och lungmedicin
Lund, Sweden
Ribocure Clinic
Mölndal, Sweden
Örebro University Hospital
Örebro, Sweden
Dalecarlia Clinical Research Center
Rättvik, Sweden
Clinical Trial Consultants Stockholm
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.